​

Relay Therapeutics (RLAY) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

RLAY Stock Forecast

Relay Therapeutics (RLAY) stock forecast, based on 14 Wall Street analysts, predicts a 12-month average price target of $16.33, with a high of $22.00 and a low of $13.00. This represents a 54.79% increase from the last price of $10.55.

- $5 $10 $15 $20 $25 High: $22 Avg: $16.33 Low: $13 Last Closed Price: $10.55

RLAY Stock Rating

Relay Therapeutics stock's rating consensus is Buy, based on 14 Wall Street analysts. The breakdown includes 1 Strong Buy (7.14%), 13 Buy (92.86%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 14 0 13 1 Strong Sell Sell Hold Buy Strong Buy

RLAY Price Target Upside V Benchmarks

TypeNameUpside
StockRelay Therapeutics54.79%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts123
Avg Price Target$22.00$18.00$16.33
Last Closing Price$10.55$10.55$10.55
Upside/Downside108.53%70.62%54.79%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26110---11
Feb, 26210---12
Jan, 26291--12
Dec, 25282--12
Nov, 25362--11
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 13, 2026Brad CaninoGuggenheim$22.00$10.81103.52%108.53%
Jan 26, 2026Oppenheimer$14.00$7.4388.43%32.70%
Dec 12, 2025Wells Fargo$13.00$7.8066.67%23.22%
Sep 16, 2024Robert BurnsH.C. Wainwright$19.00$7.60150.00%80.09%
Sep 10, 2024Akash TewariJefferies$16.00$9.5168.24%51.66%
Sep 09, 2024Peter LawsonBarclays$17.00$9.5178.76%61.14%
Sep 04, 2024Jason GerberryBank of America Securities$20.00$6.41212.01%89.57%
May 10, 2024Peter LawsonBarclays$15.00$6.68124.55%42.18%
May 06, 2024Matt BieglerOppenheimer$25.00$7.04255.11%136.97%
Apr 20, 2023Akash TewariJefferies$12.50$12.351.21%18.48%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 13, 2026GuggenheimBuyBuyhold
Jan 26, 2026OppenheimerPerformOutperformupgrade
Dec 12, 2025Wells FargoOverweightupgrade
Aug 26, 2025H.C. WainwrightBuyBuyhold
Oct 14, 2024H.C. WainwrightBuyBuyhold
Sep 16, 2024H.C. WainwrightBuyBuyhold
Sep 09, 2024OppenheimerBuyPerformdowngrade
Sep 09, 2024BarclaysOverweightOverweighthold
Sep 04, 2024Bank of America SecuritiesBuyBuyhold
Aug 07, 2024OppenheimerBuyBuyhold

Financial Forecast

EPS Forecast

$-15 $-11 $-7 $-3 $1 $5 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.82$-2.59$-2.79$-2.36$-1.61---
Avg Forecast$-3.69$-2.74$-2.83$-2.52$-2.64$-2.55$-2.48$-1.68
High Forecast$-3.08$-0.68$-2.76$-2.29$-2.20$-1.85$-1.99$0.34
Low Forecast$-4.55$-11.03$-2.93$-2.71$-3.21$-3.01$-2.80$-4.72
Surprise %3.52%-5.47%-1.41%-6.35%-39.02%---

Revenue Forecast

$0 $80M $160M $240M $320M $400M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.03M$1.38M$25.55M$10.01M$15.36M---
Avg Forecast$6.41M$4.46M$24.30M$15.08M$3.52M$20.47M$24.95M$152.86M
High Forecast$7.57M$14.83M$30.45M$48.43M$8.39M$48.83M$25.85M$364.65M
Low Forecast$5.60M$1.88M$1.17M$8.07M$268.42K$1.56M$24.06M$11.67M
Surprise %-52.76%-69.02%5.13%-33.64%336.69%---

Net Income Forecast

$-700M $-550M $-400M $-250M $-100M $50M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-363.87M$-290.51M$-341.97M$-337.71M$-276.48M---
Avg Forecast$-579.15M$-258.70M$-341.97M$-306.66M$-331.40M$-297.78M$-293.44M$-206.34M
High Forecast$-463.32M$-206.96M$-273.58M$-280.65M$-269.85M$-226.94M$-243.93M$41.42M
Low Forecast$-694.98M$-310.43M$-410.37M$-332.66M$-392.94M$-368.62M$-342.95M$-577.98M
Surprise %-37.17%12.30%-10.13%-16.57%---

RLAY Forecast FAQ

Is Relay Therapeutics stock a buy?

Relay Therapeutics stock has a consensus rating of Buy, based on 14 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 13 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Relay Therapeutics is a favorable investment for most analysts.

What is Relay Therapeutics's price target?

Relay Therapeutics's price target, set by 14 Wall Street analysts, averages $16.33 over the next 12 months. The price target range spans from $13 at the low end to $22 at the high end, suggesting a potential 54.79% change from the previous closing price of $10.55.

How does Relay Therapeutics stock forecast compare to its benchmarks?

Relay Therapeutics's stock forecast shows a 54.79% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Relay Therapeutics over the past three months?

  • March 2026: 9.09% Strong Buy, 90.91% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 16.67% Strong Buy, 83.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 16.67% Strong Buy, 75.00% Buy, 8.33% Hold, 0% Sell, 0% Strong Sell.

What is Relay Therapeutics’s EPS forecast?

Relay Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-2.55, marking a 58.39% increase from the reported $-1.61 in 2025. Estimates for the following years are $-2.48 in 2027, and $-1.68 in 2028.

What is Relay Therapeutics’s revenue forecast?

Relay Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $20.47M, reflecting a 33.31% increase from the reported $15.36M in 2025. The forecast for 2027 is $24.95M, and $152.86M for 2028.

What is Relay Therapeutics’s net income forecast?

Relay Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-298M, representing an 7.70% increase from the reported $-276M in 2025. Projections indicate $-293M in 2027, and $-206M in 2028.